Insider · CIK 0001395064
Takeda Pharmaceutical Co Ltd
Files at OVID (Ovid Therapeutics Inc.), PHAT (Phathom Pharmaceuticals, Inc.), HLVX (HilleVax, Inc.). First filing Jan 25, 2024, latest Jan 25, 2024.
In brief
Takeda Pharmaceutical Co Ltd files SEC Form 4 as 10% owner at PHAT (Phathom Pharmaceuticals, Inc.), and also at OVID (Ovid Therapeutics Inc.), HLVX (HilleVax, Inc.). Since Jan 25, 2024, Takeda Pharmaceutical Co Ltd has reported 0 open-market buys worth $0 and 1 open-market sell worth $30M, the latest filed on Jan 25, 2024.
A track record needs three past buys with six months of prices behind them; Takeda Pharmaceutical Co Ltd has 0, so none is measured yet.
The newest scored trade: sold $30M of PHAT on Jan 24, 2024, filed Jan 25, 2024, scored 55 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PHAT: Phathom Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Phathom Pharmaceuticals, Inc. | $30M 3,703,703 shares | -50% | +8% from low-57% from high |
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | OVID Ovid Therapeutics Inc. | CConversion Common Stockindirect: See Explanation of Responses | +1,250,000 | $0.00 | $0 | 7,000,000 | Dec 9, 2025 |
| Dec 8, 2025 | OVID Ovid Therapeutics Inc. | CConversion Series A Convertible Preferred Stockderivativeindirect: See Explanation of Responses | -1,250 | $0.00 | $0 | 0 | Dec 9, 2025 |
| Sep 17, 2025 | HLVX HilleVax, Inc. | UTender of shares Common Stockindirect: See Explanation of Responses | -6,724,000 | $1.95 | $13M | 0 | Sep 19, 2025 |
| Jan 24, 2024 | PHAT Phathom Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,703,703 | $8.10 | $30M | 3,755,583 | Jan 25, 2024 |
Questions about Takeda Pharmaceutical Co Ltd
Answered from the filings on this page, as of the latest one.
Is Takeda Pharmaceutical Co Ltd buying or selling?
Not in the last 12 months. Takeda Pharmaceutical Co Ltd's latest open-market trade on SEC Form 4 was sold $30M of PHAT on Jan 24, 2024.
How did Takeda Pharmaceutical Co Ltd's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Takeda Pharmaceutical Co Ltd has 0.
Where does Takeda Pharmaceutical Co Ltd file Form 4?
Takeda Pharmaceutical Co Ltd has filed Form 4 at PHAT (Phathom Pharmaceuticals, Inc.); OVID (Ovid Therapeutics Inc.); HLVX (HilleVax, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.